These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 24994946)

  • 21. Cytokine production profile in patients with Behcet's disease treated with infliximab.
    Misumi M; Hagiwara E; Takeno M; Takeda Y; Inoue Y; Tsuji T; Ueda A; Nakamura S; Ohno S; Ishigatsubo Y
    Cytokine; 2003 Dec; 24(5):210-8. PubMed ID: 14596817
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Putative Role of Serum Amyloid-A and Proinflammatory Cytokines as Biomarkers for Behcet's Disease.
    Lopalco G; Lucherini OM; Vitale A; Talarico R; Lopalco A; Galeazzi M; Lapadula G; Cantarini L; Iannone F
    Medicine (Baltimore); 2015 Oct; 94(42):e1858. PubMed ID: 26496336
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytokine inhibitors: soluble tumor necrosis factor receptor 1 and interleukin-1 receptor antagonist in Behçet's disease.
    Düzgün N; Ayaşlioğlu E; Tutkak H; Aydintuğ OT
    Rheumatol Int; 2005 Jan; 25(1):1-5. PubMed ID: 14600787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation between IL-17A/F, IL-23, IL-35 and IL-12/-23 (p40) levels in peripheral blood lymphocyte cultures and disease activity in Behcet's patients.
    Sonmez C; Yucel AA; Yesil TH; Kucuk H; Sezgin B; Mercan R; Yucel AE; Demirel GY
    Clin Rheumatol; 2018 Oct; 37(10):2797-2804. PubMed ID: 29557072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural killer cells dominate a Th-1 polarized response in Behçet's disease patients with uveitis.
    Kucuksezer UC; Aktas-Cetin E; Bilgic-Gazioglu S; Tugal-Tutkun I; Gül A; Deniz G
    Clin Exp Rheumatol; 2015; 33(6 Suppl 94):S24-9. PubMed ID: 25937098
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Production of interleukin-17 in Behcet's disease is inhibited by cyclosporin A.
    Chi W; Yang P; Zhu X; Wang Y; Chen L; Huang X; Liu X
    Mol Vis; 2010 May; 16():880-6. PubMed ID: 20508866
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imbalance of Th17 to Th1 cells in Behçet's disease.
    Kim J; Park JA; Lee EY; Lee YJ; Song YW; Lee EB
    Clin Exp Rheumatol; 2010; 28(4 Suppl 60):S16-9. PubMed ID: 20868565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Increased frequencies of interleukin-2- and interferon-gamma-producing T cells in patients with active Behçet's disease.
    Sugi-Ikai N; Nakazawa M; Nakamura S; Ohno S; Minami M
    Invest Ophthalmol Vis Sci; 1998 May; 39(6):996-1004. PubMed ID: 9579479
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vitamin D modulates peripheral immunity in patients with Behçet's disease.
    Hamzaoui K; Ben Dhifallah I; Karray E; Sassi FH; Hamzaoui A
    Clin Exp Rheumatol; 2010; 28(4 Suppl 60):S50-7. PubMed ID: 20868571
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum interleukin-6, procalcitonin and C-reactive protein levels in subjects with active Behçet's disease.
    Adam B; Calikoglu E
    J Eur Acad Dermatol Venereol; 2004 May; 18(3):318-20. PubMed ID: 15096143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum high-sensitivity C-reactive protein, tumor necrosis factor-α, interleukin (IL)-1β, IL-17A and IL-23 levels in patients with hidradenitis suppurativa.
    Saraç Öztürk G; Ergun T; Peker Eyüboğlu İ; Akkiprik M
    Cytokine; 2021 Aug; 144():155585. PubMed ID: 34034145
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of interferon-alpha2a treatment on serum levels of tumor necrosis factor-alpha, tumor necrosis factor-alpha2 receptor, interleukin-2, interleukin-2 receptor, and E-selectin in Behçet's disease.
    Kosar A; Haznedaroglu S; Karaaslan Y; Büyükasik Y; Haznedaroglu IC; Ozath D; Sayinalp N; Ozcebe O; Kirazli S; Dündar S
    Rheumatol Int; 1999; 19(1-2):11-4. PubMed ID: 10651074
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Investigating the role of IL-33 in the pathogenesis of Behçet's Disease.
    Çerçi P; Altıner S; İnal A; Köse K; Keskin G; Ölmez Ü
    Acta Clin Belg; 2017 Dec; 72(6):434-438. PubMed ID: 28412856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interleukin-17 mRNA expression and serum levels in Behçet's disease.
    Jadideslam G; Kahroba H; Ansarin K; Sakhinia E; Abhar A; Alipour S; Farhadi J; Seydi Shirvani S; Nouri-Vaskeh M; Mousavi S; Khabbazi A
    Cytokine; 2020 Mar; 127():154994. PubMed ID: 31951967
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum Levels of IL-4, IL-10, IL-12, IL-13 and IFN-gamma in Behçet's disease.
    Aridogan BC; Yildirim M; Baysal V; Inaloz HS; Baz K; Kaya S
    J Dermatol; 2003 Aug; 30(8):602-7. PubMed ID: 12928529
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytokine, C-Reactive Protein, and Heat Shock Protein mRNA Expression Levels in Patients with Active Behçet's Uveitis.
    Balkan E; Bilen H; Eyerci N; Keleş S; Kara A; Akdeniz N; Dogan H
    Med Sci Monit; 2018 Mar; 24():1511-1516. PubMed ID: 29534057
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytokines, cytokine antagonists and soluble adhesion molecules in patients with ocular Behçet's disease treated with human recombinant interferon-alpha2a. Results of an open study and review of the literature.
    Kötter I; Koch S; Vonthein R; Rückwaldt U; Amberger M; Günaydin I; Zierhut M; Stübiger N
    Clin Exp Rheumatol; 2005; 23(4 Suppl 38):S20-6. PubMed ID: 16273760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adiponectin levels, insulin resistance and their relationship with serum levels of inflammatory cytokines in patients with Behçet's disease.
    Şahin E; Karaman G; Uslu M; Karul A; Şendur N; Şavk E
    J Eur Acad Dermatol Venereol; 2012 Dec; 26(12):1498-502. PubMed ID: 22035239
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum IL-33 levels and skin mRNA expression in Behçet's disease.
    Hamzaoui K; Kaabachi W; Fazaa B; Zakraoui L; Mili-Boussen I; Haj-Sassi F
    Clin Exp Rheumatol; 2013; 31(3 Suppl 77):6-14. PubMed ID: 23464866
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of apremilast and its impact on serum cytokine levels in patients with Behçet's disease.
    Wakiya R; Ushio Y; Ueeda K; Kameda T; Shimada H; Nakashima S; Kato M; Miyagi T; Sugihara K; Mizusaki M; Mino R; Kadowaki N; Dobashi H
    Dermatol Ther; 2022 Aug; 35(8):e15616. PubMed ID: 35668044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.